Patients taking bisphosphonate therapy for symptomatic hypercalcemia; use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed
Subjects who have initiated treatment with bisphosphonates less than  days prior to the first administration of MLN (TAK-); concurrent bisphosphonate use is only allowed if the bisphosphonate was initiated at least  days prior to the first administration of MLN (TAK-)
Patients taking bisphosphonate therapy for symptomatic hypercalcemia within the past  days; use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed
Prior bisphosphonate use is permitted
Patients taking bisphosphonate therapy for symptomatic hypercalcemia; use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed
Patients taking bisphosphonate therapy for symptomatic hypercalcemia are NOT allowed; use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed
Symptomatic hypercalcemia requiring continued use of bisphosphonate or denosumab therapy
Bisphosphonates will not be allowed on the study while the participant is receiving sotatercept; prior bisphosphonate use is allowed
Patients on bisphosphonates may continue receiving bisphosphonate therapy during study treatment
Patients taking bisphosphonate therapy for symptomatic hypercalcemia; use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed
Have initiated treatment with bisphosphonates less than  days prior to study registration; concurrent bisphosphonate use is only allowed if the bisphosphonate was initiated at least  days prior to study registration
Patients on bisphosphonates may continue receiving bisphosphonate therapy during study; patients wanting to initiate bisphosphonate therapy may do so
Subjects on bisphosphonate therapy must be on a stable dose and must have started therapy >  weeks prior to protocol therapy.
Patients taking bisphosphonate therapy for symptomatic hypercalcemia; use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed
Patients on bisphosphonates may continue receiving bisphosphonate therapy during study treatment
Patients who are currently receiving bisphosphonate derivatives are not eligible
Participants on bisphosphonates may continue receiving bisphosphonate therapy during study treatment
GENERAL: Bisphosphonate therapy for symptomatic hypercalcemia\r\n* Use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed.
COHORT : HORMONE RECEPTOR POSITIVE BREAST CANCER: Patients with bone metastases who have initiated denosumab or bisphosphonate therapy within  days prior to cycle  day 
COHORT : ENDOMETRIAL CANCER: Patients with bone metastases who have initiated denosumab or bisphosphonate therapy within  days prior to cycle  day 
Initiating bisphosphonate, or RANKL antibody therapy or adjusting the dose/regimen within  days prior to cycle  day  is prohibited; patients on a stable bisphosphonate regimen are eligible and may continue
Patients taking bisphosphonate therapy for symptomatic hypercalcemia; use of bisphosphonate therapy for other reasons (e.g., osteoporosis) is allowed
Patients receiving bisphosphonate or denosumab therapy must have been on stable doses for at least  weeks prior to screening
Bisphosphonate therapy for symptomatic hypercalcemia. Use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed.
Participants on bisphosphonates may continue receiving bisphosphonate therapy during study treatment
Use of bisphosphonate therapy for osteoporosis will be allowed if started prior to study enrollment
Bisphosphonate therapy for symptomatic hypercalcemia a) Use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed
Bisphosphonate or denosumab dosage must have been stable for at least  weeks before day  for patients receiving these therapies.
The use of a RANKL inhibitor (denosumab) must be discontinued during the study; bisphosphonate therapy is permitted
Bisphosphonate therapy for symptomatic hypercalcemia\r\n* Use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed
Bisphosphonate therapy for symptomatic hypercalcemia\r\n* Use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed
Bisphosphonate therapy for symptomatic hypercalcemia\r\n* Use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed
Within  days before first dose of avelumab: therapeutic or palliative radiation therapy; (subjects receiving bisphosphonate or denosumab are eligible provided treatment was initiated at least  days before the first dose of avelumab)
Has received prior bisphosphonate therapy
Treatment within the past two years with a bisphosphonate or a Rank ligand inhibitor
Concurrent bisphosphonate therapy is not excluded, however patients should not start bisphosphonate therapy while on this study; those patients already receiving bisphosphonate therapy should continue at the same dosing and schedule as prior to study entry
Except GnRH analogue therapy, any other therapies for prostate cancer (excluding bisphosphonate and denosumab) must be discontinued  weeks before the first dose of study drugs
Have initiated treatment with bisphosphonates less than  days prior to the first administration of MLN (TAK-); concurrent bisphosphonate use is only allowed if the bisphosphonate was initiated at least  days prior to the first administration of MLN (TAK-)
Initiation or discontinuation of bisphosponate use within past  days\r\n* Continuation of use is allowed but patients must continue bisphosphonate throughout the treatment and follow up period until disease progression
Patients taking bisphosphonate therapy for symptomatic hypercalcemia\r\n* Note: use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed
Bisphosphonate therapy for symptomatic hypercalcemia (use of bisphosphonate therapy for other reasons [e.g., osteoporosis] is allowed.)
Bisphosphonate therapy for symptomatic hypercalcemia\r\n* Use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed
Initiating bisphosphonate or denosumab therapy or adjusting dose/regimen within  months prior to Cycle  Day . Subjects on a stable bisphosphonate or denosumab therapy are eligible and may continue.
Active intravenous (IV) bisphosphonate use in the last  months
Patients taking bisphosphonate therapy for symptomatic hypercalcemia; use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed
TREATMENT: Patients with bone metastases or hypercalcemia on intravenous bisphosphonate treatment, denosumab, or similar agents are eligible to participate and may continue this treatment; patients with prostate cancer may continue LHRH agonists or antagonists
Bisphosphonate therapy for symptomatic hypercalcemia\r\n* Use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed
IV bisphosphonate and denosumab for bony metastatic disease will be allowed
Patient may have received or plan to receive concurrent bone targeting agents that do not have an effect on PSA (e.g. denosumab or bisphosphonate)
Participants receiving bisphosphonate or denosumab therapy must have been on a stable dose for at least  weeks
A minimum of  days beyond initiation of bisphosphonate or denosumab therapy
High levels of calcium requiring bisphosphonate therapy or denosumab.
Intravenous (IV) bisphosphonate and denosumab for bony metastatic disease will be allowed
Participants receiving bone resorptive therapy (including but not limited to bisphosphonate or RANK-L inhibitor) must have therapy initiated at least  weeks prior to treatment allocation.
If receiving bone resorptive therapy (including but not limited to bisphosphonate or RANK-L inhibitor) must have therapy initiated at least  weeks prior to randomization.
Subjects must be on therapy with bisphosphonate and denosumab. and are required to have been on such therapy for at least  month before start of study treatment.
Treatment with bisphosphonate or denosumab within  weeks before randomisation.
Prior or ongoing bisphosphonate (e.g,. zoledronic acid) or RANKL inhibitor (e.g. denosumab) use is NOT allowed except when used solely for osteoporosis and strictly per guidelines for that indication. Bisphosphonate or RANKL inhibitor cannot be initiated for any indication during protocol specified therapy without consent of the sponsor-investigator of the study.
Bisphosphonate therapy for symptomatic hypercalcemia\r\n* Use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed
Patients taking bisphosphonate therapy for symptomatic hypercalcemia; use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed
No current anti-myeloma bisphosphonate therapy (however, prior bisphosphonates and/or bisphosphonate therapy due to osteoporosis is allowed)
Patients may have initiated bisphosphonate therapy prior to start of protocol therapy; bisphosphonate therapy may continue during protocol treatment; such patients will have bone lesions considered evaluable for progression
Current or previous chemotherapy or bisphosphonate therapy is permissible
Bisphosphonate therapy for symptomatic hypercalcemia\r\n* Use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed
Patients receiving bisphosphonate therapy or denosumab must have been on a stable dose for at least  weeks prior to enrollment
Participants must be at least  weeks out from prior chemotherapy, or other cancer-directed therapy (including novel agents), with adequate recovery of toxicity to baseline, or grade =< , with the exception of alopecia and hot flashes; washout from hormonal therapy and radiation is not required as long as participants have adequately recovered from any significant toxicities that occurred as a result from these treatments (grade  or less); participants may have initiated bisphosphonate/denosumab therapy prior to start of protocol therapy; bisphosphonate/denosumab therapy may continue during protocol treatment; such participants will have bone lesions considered evaluable for progression; washout for trastuzumab or pertuzumab is not necessary
Patients may have initiated bisphosphonate therapy prior to start of protocol therapy; bisphosphonate therapy may continue during protocol treatment; such patients will have bone lesions considered evaluable for progression
Patients receiving bisphosphonate therapy must have been on stable doses for at least  weeks with stable symptoms prior to the first infusion with ipilimumab
Patients may receive a bisphosphonate.
Patients may not initiate bisphosphonate or denosumab therapy while receiving treatment on this study; patients who have begun receiving bisphosphonate or denosumab therapy prior to registration may continue at the same intervals used prior to study registration
Patients may not initiate bisphosphonate therapy while receiving treatment on this study; patients who have begun receiving bisphosphonate therapy prior to registration may continue at the same intervals used prior to study registration
Patients taking bisphosphonate therapy for symptomatic hypercalcemia; use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed
Prior or current IV bisphosphonate administration
Uncontrolled hypercalcemia ( ?. mmol/L ionized calcium or Ca >  mg/dL) or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy or denosumab (patients receiving bisphosphonate therapy or denosumab to prevent skeletal events and who do not have a history of clinically significant hypercalcemia are eligible, though patients receiving denosumab must be willing and eligible to receive bisphosphonates instead)
Participants receiving bisphosphonate or denosumab therapy must be on stable doses for at least  weeks before start of study therapy
Subjects currently on a bisphosphonate or denosumab are eligible for study therapy
Bisphosphonate therapy for symptomatic hypercalcemia
Lack of treatment with a bisphosphonate or denosumab
Bisphosphonate therapy for symptomatic hypercalcemia
Lack of treatment with a bisphosphonate or denosumab
Initiation of bisphosphonate therapy <  weeks prior to first dose of KPT-; patients receiving bisphosphonate or denosumab therapy must be on stable doses for at least  weeks prior to first dose of KPT-
Bisphosphonate therapy for symptomatic hypercalcemia
Lack of treatment with a bisphosphonate or denosumab
Bisphosphonate therapy for symptomatic hypercalcemia
Lack of treatment with a bisphosphonate or denosumab
Symptomatic hypercalcemia requiring continued use of bisphosphonate therapy
Subject receiving bisphosphonate or denosumab therapy must have been on stable doses for at least  weeks prior to Day 
Bisphosphonate therapy currently or within the past  months
Symptomatic hypercalcemia requiring continued use of bisphosphonate therapy. Patients who are receiving bisphosphonate therapy specifically to prevent skeletal events and who do not have a history of clinically significant hypercalcemia are eligible.
Symptomatic hypercalcemia requiring continued use of bisphosphonate therapy
Concurrent bisphosphonate treatment
No radiation therapy to targeted (most painful) lesion in the past two weeks Bisphosphonate intake should remain stable throughout the study duration.
Symptomatic hypercalcemia requiring bisphosphonate or denosumab therapy
Patients undergoing bisphosphonate therapy are allowed
More than  previous dose of IV bisphosphonate administration
No prior history of bisphosphonate or denosumab use in the past  months
Patients with current or previous bisphosphonate therapy
Previous treatment with denosumab or use of bisphosphonate within  months of start of study
Uncontrolled hypercalcemia or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy or denosumab (bisphosphonate use for prevention of skeletal events allowed)
Patients who have initiated treatment with bisphosphonates less than  days prior to the first administration of MLN (TAK-) are ineligible; concurrent bisphosphonate use is only allowed if the bisphosphonate was initiated at least  days prior to the first administration of MLN (TAK-)
Patients currently using oral bisphosphonate therapy
